Mark Anthony Ashwell

USPTO Granted Patents = 45 (Patent Applications = 9)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 5.9

ph-index = 9

Forward Citations = 207(Granted Patents)

Location History:

Plainsboro, NJ (US) (2002 - 2003)
Carlisle, MA (US) (2007 - 2024)

Company Filing History:

Years Active: 2002-2025

where 'Filed Patents' based on already Granted Patents

45 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12252488 - HPK1 antagonists and uses thereof (2025-03-18),

2. 11926625 - HPK1 antagonists and uses thereof (2024-03-12),

3. 9447088 - Compositions and methods for treatment of cancer (2016-09-20),

4. 9012466 - Substituted tricyclic pyrazolo-pyrimidine compounds (2015-04-21),

5. 8962619 - Substituted imidazopyridinyl-aminopyridine compounds (2015-02-24),

6. 8815854 - Substituted imidazopyridinyl compounds (2014-08-26),

7. 8754078 - Compositions and methods for treatment of cancer (2014-06-17),

8. 8614228 - Quinone prodrug compositions and methods of use (2013-12-24),

9. 8609688 - Substituted imidazopyridinyl-aminopyridine compounds (2013-12-17),

10. 8569331 - Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds (2013-10-29),

11. 8563567 - Substituted heterocyclic compounds (2013-10-22),

12. 8541407 - Substituted benzo-pyrido-triazolo-diazepine compounds (2013-09-24),

13. 8513292 - Compositions and methods for the treatment of cancer (2013-08-20),

14. 8501770 - Substituted imidazopyridinyl-aminopyridine compounds (2013-08-06),

15. 8470786 - Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same (2013-06-25),

Title: Mark Anthony Ashwell: Innovations in Cancer Treatment and Beyond

Introduction:

Mark Anthony Ashwell, a prolific inventor based in Carlisle, MA, has made significant contributions to the field of medical science through his numerous patents. With a remarkable total of 43 patents to his name, Ashwell's inventive spirit has been dedicated to advancing the treatment of cell proliferative disorders, particularly cancer. This article will delve into his latest patents, career highlights, notable collaborations, and highlight the impact of his innovations.

Latest Patents:

Ashwell's latest patents demonstrate his focus on developing novel treatments for cancer. One notable patent involves the use of pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. This invention offers an innovative method for treating cell proliferative disorders by administering a combination of these compounds and conventional chemotherapeutic agents. Such an approach may enhance the efficacy of cancer treatments and provide new avenues for combating the disease.

Another recent patent by Ashwell involves substituted tricyclic pyrazolo-pyrimidine compounds. These compounds and their synthesis methods offer potential for treating cell proliferative disorders, including cancer. Pharmaceutical compositions containing these compounds showcase their therapeutic potential, making them instrumental in advancing cancer treatment options.

Career Highlights:

Over the years, Ashwell has made significant strides in his career, working with notable companies and making valuable contributions to the field. He has been associated with renowned organizations like Arqule, Inc. and Wyeth (now part of Pfizer), where he has likely gained exposure to cutting-edge research and development in the pharmaceutical industry. The experiences gained from these collaborations undoubtedly influenced his inventive journey.

Collaborations:

Ashwell has had the privilege of working alongside talented individuals in his field. Notably, he has collaborated with Manish Tandon and Yanbin Liu, possibly fostering a dynamic exchange of ideas and accelerating the pace of innovation. Collaborative efforts can often lead to breakthroughs by leveraging diverse expertise and perspectives, and Ashwell's collaborations are a testament to the value of teamwork in the world of inventions and patents.

Conclusion:

Mark Anthony Ashwell's impressive portfolio of patents showcases his deep commitment to advancing cancer treatment methodologies. His research on pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and substituted tricyclic pyrazolo-pyrimidine compounds has opened new possibilities for combating cell proliferative disorders, particularly cancer. Ashwell's career highlights and collaborations highlight the importance of multidisciplinary approaches and knowledge-sharing in the pursuit of groundbreaking innovations. As his inventive journey continues, we eagerly anticipate the further contributions he will make to the field of medical science, ultimately improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.